Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation

Neurology

Volumn 61, Issue 11 SUPPL. 6, 2003, Pages

  Weiss, Scott M ^a   Whawell, Emma ^a   Upton, Rebecca ^a   Dourish, Colin T ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; ISTRADEFYLLINE; NEUROLEPTIC AGENT; THEOPHYLLINE;

ARTICLE; CORPUS STRIATUM; DRUG EFFECT; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HYPOTENSION; NONHUMAN; PRIORITY JOURNAL;

EID: 0344738698     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000095221.30476.8a     Document Type: Article

References (52)

1. 2A receptors. Prog Neurobiol 1999;59:355-396.
2. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
3. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997;18:338-344.
4. 2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 1997;17:82-91.
5. Ferre S. Adenosine-dopamine interactions in the ventral striatum: implications for the treatment of schizophrenia. Psychopharmacology 1997;133:107-120.
6. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The functional state of the dopamine receptor in the anterior pituitary is the high affinity form. Endocrinology 1985;117:690-697.
7. Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001;53:119-133.
8. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-483.
9. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38.
10. Jenner P, Marsden CD. Neuroleptics and tardive dyskinesia. In: Coyte JT, Enna SJ, eds. Neuroleptics: Neurochemical, Behavioral and Clinical Perspectives. New York: Raven Press, 1983:223-253.
11. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;28(suppl 1):9-26.
12. Westerink BH. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol 2002;455:1-18.
13. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001;52:503-517.
14. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-152.
15. Wolters EC. Intrinsic and extrinsic psychosis in Parkinson's disease. J Neurol 2001;248(suppl 3):III22-27.
16. Hollister LE. Drug-induced psychiatric disorders and their management. Med Toxicol 1986;1:428-448.
17. Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 1999;52:S10-13.
18. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 1994;63:765-773.
19. 2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 1996;295:147-154.
20. Robbins TW, Everitt B. Functions of dopamine in the dorsal and ventral striatum. Semin Neurosci 1992;4:119-127.
21. Robertson GS, Fibiger HC. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992;46:315-328.
22. Salamone JD. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav Brain Res 1994;61:117-133.
23. Ögren SO. The behavioural pharmacology of typical and atypical antipsychotic drugs. In: Csernansky JG, ed. Handbook of Experimental Pharmacology (Antipsychotics). Berlin: Springer, 1996:225-265.
24. 2A receptors in the nucleus accumbens mediate locomotor depression. Brain Res Bull 1993;31:397-404.
25. Zarrindast MR, Modabber M, Sabetkasai M. Influences of different adenosine receptor subtypes on catalepsy in mice. Psychopharmacology 1993;113:257-261.
26. Heffner TG, Wiley JN, Williams AE, Bruns RF, Coughenour LL, Downs DA. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology 1989;98:31-37.
27. 2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur J Pharmacol 1998;347:153-158.
28. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.
29. Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 1995;120:128-133.
30. 2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav Pharmacol 2002;13:639-644.
31. 2A receptors in the nucleus accumbens and the caudate-putamen. Eur J Pharmacol 1997;323:127-131.
32. 2A receptor agonist, CGS 21680, on blood pressure, cardiac index and arterial conductance in anaesthetized rats. Eur J Pharmacol 1996;307:163-169.
33. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001;156:234-258.
34. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001;156:117-154.
35. 2A receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. Neuroreport 1997;8:1515-1518.
36. 2A agonist CGS 21680 reverses the reduction in prepulse inhibition of the acoustic startle response induced by phencyclidine, but not by apomorphine and amphetamine. Psychopharmacology (Berl) 2001;156:187-193.
37. 2A receptors in the rat striatum induces catalepsy that is reversed by antagonists of N-methyl-D-aspartate receptors. Neurosci Lett 1995;196:205-208.
38. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 1995;287:215-217.
39. 2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. Neuroreport 1999;10:687-691.
40. Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J Neurosci 2000;20:7782-7789.
41. Bakshi VP, Geyer MA, Taaid N, Swerdlow NR. A comparison of the effects of amphetamine, strychnine and caffeine on prepulse inhibition and latent inhibition. Behav Pharmacol 1995;6:801-809.
42. Koch M, Hauber W. Regulation of sensorimotor gating by interactions of dopamine and adenosine in the rat. Behav Pharmacol 1998;9:23-29.
43. 2A receptor antagonist, KW-6002, on pre-pulse inhibition in the rat. J Psychopharm 2001;S15:A50.
44. Hughes JR, McHugh P, Holtzman S. Caffeine and schizophrenia. Psychiatr Serv 1998;49:1415-1417.
45. Clementz GL, Dailey JW. Psychotropic effects of caffeine. Am Fam Physician 1988;37:167-172.
46. Mackay DC, Rollins JW. Caffeine and caffeinism. J R Nav Med Serv 1989;75:65-67.
47. Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D. Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 1990;28:35-40.
48. Mayo KM, Falkowski W, Jones CA. Caffeine: use and effects in long-stay psychiatric patients. Br J Psychiatry 1993;162:543-545.
49. Koczapski A, Paredes J, Kogan C, Ledwidge B, Higenbottam J. Effects of caffeine on behavior of schizophrenic inpatients. Schizophr Bull 1989;15:339-344.
50. Akhondzadeh S, Shasavand E, Jamilian H, Shabestari O, Kamalipour A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J Clin Pharm Ther 2000;25:131-137.
51. Soderling SH, Bayuga SJ, Beavo JA. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 1998;95:8991-8996.
52. 1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat. Eur J Pharmacol 1999;369:325-329.